ValuentumAd

Official PayPal Seal
Valuentum Reports













Fundamental data is updated weekly, as of the prior weekend. Please download the Full Report and Dividend Report for any changes.
Latest Valuentum Commentary

Oct 28, 2015
Around the Horn in Biotech/Pharma: 3Q Earnings Review
Abbott, Biogen, Bristol-Myers, Eli Lilly, Gilead, GlaxoSmithKline, Merck, Pfizer…
Oct 26, 2015
If It Happened to AbbVie, Could It Also Happen to Gilead?
Recent news concerning AbbVie’s hepatitis C drugs caused a severe decline in the company’s share price. Could such an event happen to Gilead?
Oct 16, 2015
Johnson & Johnson: A Dividend Growth Gem
Johnson & Johnson continues to grow on an operational basis, and its pharmaceutical pipeline may offer huge rewards in coming years. We’re huge fans of its financial profile and lofty dividend coverage.
Aug 31, 2015
5 High-Yielding Strong Dividend Growth Stocks for the Long Haul
Let’s have a look at some of our favorite dividend growth stocks on the market today.
Jul 17, 2015
J&J’s Quarterly Results Not Reflective of Underlying Strength
On the surface, Johnson & Johnson’s second-quarter results weren’t that great, but let’s take a closer look at the performance.
May 30, 2015
Are Corporate Credit Ratings Really Useful?
S&P’s move this week tells you how influenced, not influential, the major rating agencies have become.
Apr 15, 2015
Johnson & Johnson Finetunes 2015 Guidance
J&J has been a powerful contributor to the annualized return of the Dividend Growth portfolio.
Mar 20, 2015
Hooray! Biogen’s Breakthrough Alzheimer’s Drug?
Biogen’s potential new drug could help millions of people suffering from Alzheimer’s.
Jan 20, 2015
Video: Johnson & Johnson Still Strong Dividend Growth Idea
Valuentum's President Brian Nelson talks about J&J's solid dividend growth prospects and budding late stage pharma pipeline in the EU and US.
Jan 5, 2015
4 Opportunistic Stocks To Consider Buying in 2015
The Valuentum Buying Index has registered a high rating in the past on these four investment ideas. 2015 may mark strong gains for these gems.


Latest News and Media
The High Yield Dividend Newsletter, Best Ideas Newsletter, Dividend Growth Newsletter, Nelson Exclusive publication, and any reports, articles and content found on this website are for information purposes only and should not be considered a solicitation to buy or sell any security. The sources of the data used on this website are believed by Valuentum to be reliable, but the data’s accuracy, completeness or interpretation cannot be guaranteed. Valuentum is not responsible for any errors or omissions or for results obtained from the use of its newsletters, reports, commentary, or publications and accepts no liability for how readers may choose to utilize the content. Valuentum is not a money manager, is not a registered investment advisor and does not offer brokerage or investment banking services. Valuentum, its employees, and affiliates may have long, short or derivative positions in the stock or stocks mentioned on this site.